慢性淋巴细胞白血病中的acalabrutinib:药理学和新兴的临床前景
Gianluca Gaidano1, Romano Danesi2
1Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara, Italy.
European journal of haematology
|February 25, 2026
概括
作为慢性淋巴细胞白血病 (CLL) 的向疗法,阿卡拉布鲁丁尼 (acalabrutinib) 显示出高疗效和改善的安全性. 这种布鲁顿的氨酸激酶抑制剂 (BTKi) 提供了比较古老的治疗方法更少的副作用的持久生存益处.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿卡拉布鲁丁尼布代表了慢性淋巴细胞白血病 (CLL) 向治疗的进步.
- 它是第二代布鲁顿的氨酸激酶抑制剂 (BTKi),对BTK具有很高的特异性.
研究的目的:
- 评估acalabrutinib在治疗CLL中的疗效和安全性.
- 评估基于acalabrutinib的治疗方案的长期结果和耐受性.
主要方法:
- 从关键的III期临床试验中分析长期数据.
- 研究acalabrutinib的作用机制,包括对BTK的共价结合.
- 确定时间的组合疗法的评估.
主要成果:
- 阿卡拉布鲁丁尼在以前未接受治疗和复发/耐药的CLL患者中表现出高疗效.
- 观察到持久的无进展生存率和有利的整体生存率.
- 与第一代BTKi相比,心房动和高血压等严重不良事件的发病率较低,耐受性更好,中止率更低.
结论:
- 阿卡拉布鲁丁尼布是一种高效且耐受性良好的CLL治疗方法.
- 固定的时间组合显示持续的最小残留疾病 (MRD) 消极性.
- 阿卡拉布鲁丁尼为个性化的CLL治疗提供了灵活的基石.
相关概念视频
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
646
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
646
Drug Clearance: Overview
501
Drug elimination refers to drug removal from the body, either through urine or bile, by the kidneys or liver, respectively. A pharmacokinetic parameter, drug clearance, measures the efficiency of drug removal from the bloodstream within a specific time frame. It is calculated as the rate at which a drug is eliminated from plasma divided by the drug's concentration in plasma.
Drug clearance is not limited to renal excretion but encompasses all organs involved in drug elimination, including...
Drug clearance is not limited to renal excretion but encompasses all organs involved in drug elimination, including...
501
Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Pharmacodynamics: Overview and Principles
3.6K
Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
3.6K
Drug Administration and Therapy Phases: Overview
1.5K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.5K


